The first-ever NASH drug may be around the corner from being approved by the Food and Drug Administration. Intercept Pharmaceuticals announced recently that a potential therapy for the fatty liver disease known as NASH had achieved its primary goal in a Phase 3 trial. The news follows Gilead Sciences Inc. announcing that a competing trial … Continue reading “The FDA May Be Close to Approving Intercept Pharmaceuticals’ NASH Drug”
